Table 3.
Multivariate Analysis Predicting Overall Survival and Recurrence-Free Survival.
| Variable | Overall Survival | Recurrence-Free Survival | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age, years (≥69 vs <69) | 1.06 (0.41-2.74) | .900 | 0.63 (0.26-1.48) | .286 |
| Sex (female vs male) | 0.71 (0.22-2.24) | .554 | 0.62 (0.24-1.61) | .326 |
| Performance status (≥1 vs 0) | 0.99 (0.41-2.42) | .664 | 1.17 (0.51-2.70) | .706 |
| ACCI score (≥4 vs 0-3) | 0.90 (0.70-1.16) | .431 | 1.01 (0.80-1.26) | .948 |
| Hydronephrosis (present vs absent) | 1.93 (0.70-5.35) | .204 | 1.96 (0.79-4.83) | .144 |
| Carcinoma in situ (present vs absent) | 0.45 (0.11-1.15) | .133 | 0.52 (0.19-1.39) | .193 |
| Multifocality (multiple vs single) | 4.66 (1.54-14.07) | .006 | 3.54 (1.31-9.59) | .013 |
| NLR (≥2.35 vs <2.35) | 3.06 (1.00-9.40) | .049 | 2.78 (1.10-7.01) | .031 |
| CRP, mg/dL (≥0.14 vs <0.14) | 1.33 (0.53-3.37) | .546 | 1.06 (0.46-2.46) | .889 |
| Hemoglobin, g/dL (<12.5 vs ≥12.5) | 1.87 (0.66-5.27) | .236 | 1.06 (0.44-2.53) | .902 |
| Neoadjuvant chemotherapy (yes vs no) | 0.63 (0.21-1.80) | .410 | 0.64 (0.24-1.69) | .366 |
| Pathologic T stage (≥T3 vs ≤T2) | 3.23 (1.13-9.20) | .028 | 2.67 (1.08-6.58) | .033 |
| Pathologic N stage (positive vs negative) | 4.68 (1.45-15.05) | .005 | 2.91 (1.75-5.86) | .028 |
| Lymphovascular invasion (positive vs negative) | 2.32 (0.49-10.95) | .286 | 5.83 (1.62-20.94) | .007 |
| No. of lymph node removed (≥9 vs <9) | 0.97 (0.91-1.04) | .433 | 0.96 (0.89-1.02) | .183 |
| Adjuvant chemotherapy (yes vs no) | 1.05 (0.44-2.52) | .916 | 0.34 (0.09-1.33) | .122 |
| Squamous differentiation (present vs absent) | 4.22 (1.20-14.80) | .024 | 2.13 (0.74-6.15) | .064 |
Abbreviations: ACCI, age-adjusted Charlson comorbidity index; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio.